Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance)

Rituximab monotherapy has proven efficacy in treatment-naïve, asymptomatic advanced-stage follicular lymphoma (FL). Ofatumumab is a fully humanized anti-CD20 monoclonal antibody with increased CD20 affinity and complement-dependent cytotoxicity. This phase 2 trial (NCT01190449) evaluated ofatumumab...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Br J Haematol
Glavni autori: Rosenbaum, Cara A., Jung, Sin-Ho, Pitcher, Brandelyn, Bartlett, Nancy L., Smith, Sonali M., Hsi, Eric, Wagner-Johnston, Nina, Thomas, Sachdev P., Leonard, John P., Cheson, Bruce D.
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6462222/
https://ncbi.nlm.nih.gov/pubmed/30723894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15768
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items